INDGN Indegene Q3 FY26 results (Oct–Dec 2025) and concall
Indegene delivered a strong Q3 FY26, characterized by significant revenue acceleration driven by the BioPharm acquisition and healthy organic growth. While margins were impacted by one-time acquisition costs and a sharp rise in non-cash amortization, management provided a clear roadmap for EBITDA margins to return to 20% within 6-8 quarters. The company is aggressively positioning its Gen AI platforms to drive industry centralization and 'agency-less' models.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 1.0%, net profit down 30.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 282 | 287 | 267 | 256 | 307 +9% | 290 +1% |
| EBITDA | 46 | 52 | 40 | 37 | 71 +54% | 38 −27% |
| Net profit | 45 | 50 | 54 | 45 | 60 +33% | 35 −30% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
